CoChat

Does a Patient-Managed Insulin Intensification Strategy With Insulin Glargine and Insulin Glulisine Provide Similar Glycemic Control as a Physician-Managed Strategy? Results of the START (Self-Titration With Apidra to Reach Target) Study

Harris, Stewart B., Yale, Jean-François, Berard, Lori, Stewart, John, Abbaszadeh, Babak, Webster-Bogaert, Susan, Gerstein, Hertzel C. · 2014 · Diabetes Care
Cited by 19

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: Diabetes self-management is universally regarded as a foundation of diabetes care. We determined whether comparable glycemic control could be achieved by self-titration versus physician titration of a once-daily bolus insulin dose in patients with type 2 diabetes who are unable to achieve optimal glycemia control with a basal insulin. RESEARCH DESIGN AND METHODS: Patients with type 2 diabetes, an HbA1c level >7% (53 mmol/mol), and either nocturnal hypoglycemia episodes or an insufficient basal insulin glargine level (with or without oral agents) to achieve a fasting plasma glucose level ≤6 mmol/L (108 mg/dL) were studied. Participants all had bolus insulin glulisine added at breakfast and were allocated to either algorithm-guided patient self-titration or physician titration. The primary outcome was an HbA1c level ≤7% (53 mmol/mol) without severe hypoglycemia. RESULTS: After a mean (SD) follow-up of 159.4 days (36.2 days), 28.4% of participants in the self-titration arm vs. 21.2% in the physician titration arm achieved an HbA1c level of ≤7% (53 mmol/mol) without severe hypoglycemia (between-group absolute difference 7.2%; 95% CI −3.2 to 17.7). The lower end of this 95% confidence interval was within the predetermined noninferiority boundary of −5% (P noninferiority = 0.011). CONCLUSIONS: In stable patients with type 2 diabetes who are receiving doses of basal insulin glargine who require bolus insulin, a simple bolus insulin patient-managed titration algorithm is as effective as a physician-managed algorithm.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc13-1636

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 24

  1. Wright, 2002, Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57), Diabetes Care, 25, 330, 10.2337/diacare.25.2.330 · DOI · Paper page
  2. Jaakkimainen, 2003, Sources of physician care for people with diabetes, 181
  3. Harris, 2010, Clinical inertia in patients with T2DM requiring insulin in family practice, Can Fam Physician, 56, e418
  4. Yki-Järvinen, 2004, Insulin therapy in type 2 diabetes: role of the long-acting insulin glargine analogue, Eur J Clin Invest, 34, 410, 10.1111/j.1365-2362.2004.01356.x · DOI
  5. Chapman, 2002, Insulin aspart: a review of its use in the management of type 1 and 2 diabetes mellitus, Drugs, 62, 1945, 10.2165/00003495-200262130-00014 · DOI
  6. Gerstein, 2006, A randomized trial of adding insulin glargine vs. avoidance of insulin in people with type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study, Diabet Med, 23, 736, 10.1111/j.1464-5491.2006.01881.x · DOI · Paper page
  7. Harris, 2008, Can family physicians help patients initiate basal insulin therapy successfully? Randomized trial of patient-titrated insulin glargine compared with standard oral therapy: lessons for family practice from the Canadian INSIGHT trial, Can Fam Physician, 54, 550
  8. Meece, 2006, Dispelling myths and removing barriers about insulin in type 2 diabetes, Diabetes Educ, 32, 9S, 10.1177/0145721705285638 · DOI · Paper page
  9. Monnier, 2007, The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes, Diabetes Care, 30, 263, 10.2337/dc06-1612 · DOI · Paper page
  10. Monnier, 2011, Postprandial and basal glucose in type 2 diabetes: assessment and respective impacts, Diabetes Technol Ther, 13, S25, 10.1089/dia.2010.0239 · DOI · Paper page
  11. Peter, 2009, Relative and absolute contributions of postprandial and fasting plasma glucose to daytime hyperglycaemia and HbA(1c) in subjects with type 2 diabetes, Diabet Med, 26, 974, 10.1111/j.1464-5491.2009.02809.x · DOI
  12. Ceriello, 2010, The glucose triad and its role in comprehensive glycaemic control: current status, future management, Int J Clin Pract, 64, 1705, 10.1111/j.1742-1241.2010.02517.x · DOI
  13. Pearson, 2006, Systematically initiating insulin: the staged diabetes management approach, Diabetes Educ, 32, 19S, 10.1177/0145721705285640 · DOI
  14. Inzucchi, 2012, Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), Diabetes Care, 35, 1364, 10.2337/dc12-0413 · DOI · Paper page
  15. Davidson, 2011, A stepwise approach to insulin therapy in patients with type 2 diabetes mellitus and basal insulin treatment failure, Endocr Pract, 17, 395, 10.4158/EP10323.OR · DOI
  16. Lankisch, 2008, Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs, Diabetes Obes Metab, 10, 1178, 10.1111/j.1463-1326.2008.00967.x · DOI · Paper page
  17. Raccah, 2007, When basal insulin therapy in type 2 diabetes mellitus is not enough—what next?, Diabetes Metab Res Rev, 23, 257, 10.1002/dmrr.733 · DOI · Paper page
  18. Bradley, 2007, The Diabetes Treatment Satisfaction Questionnaire change version (DTSQc) evaluated in insulin glargine trials shows greater responsiveness to improvements than the original DTSQ, Health Qual Life Outcomes, 5, 57, 10.1186/1477-7525-5-57 · DOI · Paper page
  19. Selam, 2009, Basal-bolus therapy with insulin detemir using the 303 algorithm in the US PREDICTIVE 303 trial, 194
  20. Peyrot, 2005, Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study, Diabetes Care, 28, 2673, 10.2337/diacare.28.11.2673 · DOI · Paper page
  21. Davis, 2006, Psychological insulin resistance: overcoming barriers to starting insulin therapy, 146S
  22. Kunt, 2009, Barriers to insulin initiation and intensification and how to overcome them, 6
  23. Peyrot, 2004, Psychological insulin resistance: overcoming barriers to insulin therapy, Practical Diabetology, 23, 6
  24. Funnell, 2004, Empowerment and self-management of diabetes, 123

Cited by

See all 19

Metadata

Authors
Harris, S. B., Yale, J.-F., Berard, L., Stewart, J., Abbaszadeh, B., Webster-Bogaert, S., & Gerstein, H. C.
Affiliations
  • Department of Family Medicine, The University of Western Ontario, London, Ontario, Canada
  • Department of Medicine, McGill University, Montreal, Quebec, Canada
  • Winnipeg Regional Health Authority, Health Sciences Centre, Winnipeg Diabetes Research Group, Winnipeg, Manitoba, Canada
  • Sanofi Canada, Medical and Regulatory Affairs, Montreal, Quebec, Canada
  • Department of Medicine, McMaster University, Hamilton, Ontario, Canada
Venue
Diabetes Care
Published
2014-02-11
Volume
37
Issue
3
Pages
604-610
ISSN
  • 0149-5992
  • 1935-5548
Cited by
19
References
10
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Does a Patient-Managed Insulin Intensification Strategy With Insulin Glargine and Insulin Glulisine Provide Similar Glycemic Control as a Physician-Managed Strategy? Results of the START (Self-Titration With Apidra to Reach Target) Study. https://app.cochat.ai/papers/10.2337/dc13-1636
The paper
Harris, S. B., Yale, J.-F., Berard, L., Stewart, J., Abbaszadeh, B., Webster-Bogaert, S., & Gerstein, H. C. (2014). Does a Patient-Managed Insulin Intensification Strategy With Insulin Glargine and Insulin Glulisine Provide Similar Glycemic Control as a Physician-Managed Strategy? Results of the START (Self-Titration With Apidra to Reach Target) Study. Diabetes Care. https://doi.org/10.2337/dc13-1636

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.